Reviews/Novel Antibiotics/CAZ-AVI plus aztreonam is effective against MBL-producing organisms
Caz Avi · NOVEL-AB-CAZAVI-02 · v2
The question is whether ceftazidime-avibactam combined with aztreonam actually works against bacteria that make metallo-beta-lactamase enzymes, which disable most last-line antibiotics. The most direct evidence here is a laboratory test showing that adding ceftazidime-avibactam restored aztreonam's activity in 35 of 37 NDM-producing isolates [7], which is a strong microbiological signal but not a measure of whether patients get better. The only clinical trial of the aztreonam-avibactam principle [2] used the licensed fixed-dose product rather than the two-drug off-label regimen the claim names, and did not select for MBL patients, so it cannot show effectiveness specifically against MBL infections. The papers that state most plainly that this pairing works against MBLs are all review articles [11][9], which the panel's method excluded from scoring. So the biological rationale is well supported, while proof of patient-level effectiveness against MBL organisms is still missing from this corpus.
At the microbiological level the corpus supports the combination: [7] found that of 37 carbapenem-resistant NDM-producing isolates, 35 (94.6%) tested synergy positive when aztreonam was paired with ceftazidime-avibactam, with sensitivity 97.14% and specificity 100% against the broth microdilution reference. The only clinical efficacy data for the avibactam-plus-aztreonam principle come from REVISIT [2], where 193 (68.4%) of 282 aztreonam-avibactam patients reached clinical cure versus 92 (65.7%) of 140 on meropenem (treatment difference 2.7% [95% CI -6.6 to 12.4]). But [2] used the fixed-combination aztreonam-avibactam, enrolled a Gram-negative population that was not MBL-selected, and only 19 (24%) of 80 isolates tested for carbapenemases were positive, pooling serine and metallo-beta-lactamase. No clinical trial restricted to MBL-infected patients exists in the eligible corpus. The contested point: The division is between microbiological synergy and demonstrated clinical effectiveness: [7] establishes the former in NDM isolates with no patient outcomes, while [2] offers a clinical signal that is indirect because it uses a different formulation and a non-MBL-selected population. Whether in vitro restoration of aztreonam activity translates into cure in MBL-infected patients is the unbridged step.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest direct evidence [7] measures in vitro synergy (restoration of aztreonam zone diameter crossing a susceptibility breakpoint), a microbiological surrogate — not clinical cure in patients with MBL infections. 'Effective' is not demonstrated at the clinical level.
REVISIT [2] studies the licensed fixed-dose aztreonam-avibactam, not the off-label CAZ-AVI plus aztreonam the claim names, was open-label and descriptive with no planned hypothesis testing, and was not MBL-selected (carbapenemase-positives pooled serine + MBL). It cannot isolate efficacy against MBL producers.
Where it remains uncertain. The direct evidence [7] is an in vitro surrogate in NDM-only isolates, and the clinical trial [2] used a different, fixed-dose formulation in a population that was not MBL-selected, so neither isolates effectiveness against MBL-producing organisms in patients.
Aleatory
[7] rests on 37 NDM isolates from a single centre, a limited sample for characterising synergy across MBL producers.
Epistemic
No clinical trial restricted to MBL-infected patients exists in the eligible corpus; [2] was not MBL-selected and only 19 of 80 tested isolates were carbapenemase-positive.
Inferential
The chain from in vitro zone-diameter restoration [7] to clinical effectiveness in patients is not closed by any corpus paper.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Clinical efficacy of the avibactam+aztreonam principle, but non-comparative/descriptive and in a mixed population not selected for MBL.
“Overall, 19 (24%) of 80 isolates tested for carbapenemases were carbapenemase-positive (serine, metallo-β-lactamase, or both).”
Panel auditInternal validity: medium · scope of inference: Adults with cIAI or HAP-VAP caused or suspected to be caused by Gram-negative bacteria, mostly Enterobacterales, treated with aztreonam-avibactam.Key limitations: no MBL subgroup efficacy reported · open-label descriptive design · different product than CAZ-AVI plus aztreonam
Direct in vitro evidence that CAZ-AVI restores aztreonam activity against MBL (NDM) producers in nearly all isolates tested.
“Combination therapy of aztreonam and ceftazidime-avibactam is a prudent choice for these infections.”
Panel auditInternal validity: medium · scope of inference: In vitro synergy of aztreonam plus ceftazidime-avibactam in NDM-producing Enterobacterales clinical isolates.Key limitations: in vitro only, no clinical effectiveness · NDM only, not other MBL types · primarily a methods-validation paper · small isolate number
2 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
MBL-selected clinical trial of the two-drug regimen. The corpus has no patient-outcome trial restricted to MBL producers using CAZ-AVI plus aztreonam, which is the exact intervention and population the claim names. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective trial enrolling patients with confirmed MBL-producing infections randomised to CAZ-AVI plus aztreonam, reporting clinical cure and mortality.
Open question: Does CAZ-AVI plus aztreonam produce clinical cure in patients with confirmed MBL-producing infections? Why it is still open: The only clinical trial [2] used the fixed-dose formulation in a non-MBL-selected population, so no eligible source answers this directly.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19